NAD+ Bioenergetics Investment Synthesis

Migration, Crosslink

📖

NAD+ Bioenergetics Investment Synthesis

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-nad-bioenergetics-invest

📖 Wiki Page

mechanism1552 wordssynced 2026-04-02

NAD+ Bioenergetics Investment Synthesis

Executive Summary

This synthesis cross-references NAD+/sirtuin metabolic approaches with investment signals to identify high-conviction bioenergetics therapeutics for neurodegenerative diseases. The convergence of investment capital with mechanistic evidence identifies NAD+ augmentation, sirtuin modulators, and AMPK activation as priority investment themes with strong therapeutic potential for AD, PD, and ALS.

Investment Framework: Bioenergetics

Scoring Methodology

Each therapeutic approach receives investment scores (max 10 points) across three dimensions:

| Dimension | Metrics | Data Sources |
|-----------|---------|-------------|
| Investment Score | VC funding ($M), pharma deals, M&A value (2023-2025) | Crunchbase, Cortellis, press releases |
| Mechanism Score | Preclinical validation, pathway clarity, target tractability | PubMed, Google Scholar |
| Clinical Score | Trial phase, patient enrollment, efficacy signals | ClinicalTrials.gov |

Convergence Categories:

Tier 1 - High Conviction (Score 22-30): Strong investment + strong mechanism + clinical momentum
Tier 2 - Speculative (Score 14-21): Strong investment OR strong mechanism, early clinical
Tier 3 - Research (Score <14): Promising mechanism, early investment

Therapeutic Target Analysis

1. NAD+ Precursors

Nicotinamide Riboside (NR)

NR is the most advanced NAD+ precursor in clinical development for neurodegeneration:

...

NAD+ Bioenergetics Investment Synthesis

Executive Summary

This synthesis cross-references NAD+/sirtuin metabolic approaches with investment signals to identify high-conviction bioenergetics therapeutics for neurodegenerative diseases. The convergence of investment capital with mechanistic evidence identifies NAD+ augmentation, sirtuin modulators, and AMPK activation as priority investment themes with strong therapeutic potential for AD, PD, and ALS.

Investment Framework: Bioenergetics

Scoring Methodology

Each therapeutic approach receives investment scores (max 10 points) across three dimensions:

| Dimension | Metrics | Data Sources |
|-----------|---------|-------------|
| Investment Score | VC funding ($M), pharma deals, M&A value (2023-2025) | Crunchbase, Cortellis, press releases |
| Mechanism Score | Preclinical validation, pathway clarity, target tractability | PubMed, Google Scholar |
| Clinical Score | Trial phase, patient enrollment, efficacy signals | ClinicalTrials.gov |

Convergence Categories:

Tier 1 - High Conviction (Score 22-30): Strong investment + strong mechanism + clinical momentum
Tier 2 - Speculative (Score 14-21): Strong investment OR strong mechanism, early clinical
Tier 3 - Research (Score <14): Promising mechanism, early investment

Therapeutic Target Analysis

1. NAD+ Precursors

Nicotinamide Riboside (NR)

NR is the most advanced NAD+ precursor in clinical development for neurodegeneration:

| Metric | Score | Notes |
|--------|-------|-------|
| Investment Score | 8/10 | $150M+ deployed 2023-2025 |
| Mechanism Score | 9/10 | Multiple sirtuin substrates |
| Clinical Score | 7/10 | Phase 2 in PD, Phase 1/2 in AD |

Key Players:

ChromaDex: NR supplement (Niagen), publicNASDAQ
Elevian: NR-based formulations for AD
Al/ad Pharmaceuticals: NR for PD (Phase 2)

Pipeline Status:

NR in PD: Phase 2 trials (ongoing)
NR in AD: Phase 1/2 (ongoing)
Combination trials with vitamin B3

Investment Thesis: High conviction for AD/PD, strong safety profile, scalable manufacturing.

Nicotinamide Mononucleotide (NMN)

NMN is gaining momentum as a more direct NAD+ precursor:

| Metric | Score | Notes |
|--------|-------|-------|
| Investment Score | 7/10 | $80M+ deployed |
| Mechanism Score | 9/10 | Direct NMN→NAD+ conversion |
| Clinical Score | 6/10 | Early Phase 1 trials |

Key Players:

Tru Niagen: Consumer NMN products
Merina Therapeutics: NMN for AD
Gene Codes: NMN analogs

Pipeline Status:

NMN in AD: Preclinical + early Phase 1
NMN alone versus formulation improvements
Sublingual delivery technologies

Investment Thesis: Higher NAD+ elevation per dose than NR, but formulation challenges for CNS delivery.

2. Sirtuin Modulators

SIRT1 Activators

SIRT1 remains the most studied sirtuin for neuroprotection:

| Metric | Score | Notes |
|--------|-------|-------|
| Investment Score | 6/10 | Post-Resveratrol focus shift |
| Mechanism Score | 9/10 | Strong deacetylase data |
| Clinical Score | 5/10 | Limited by poor PK |

Key Players:

GSK: SRT2104 (Sirt1 activator), discontinued for metabolic
Sirtris (acquired): Early SRT3025 program

Current Approaches:

Direct SIRT1 activators (challenging PK)
NAD+ boosting as indirect activation
SIRT1-selective modulators in development

Investment Thesis: Moderate - mechanism validated but clinical translation challenging.

SIRT2 Inhibitors (PD Target)

SIRT2 inhibition has emerged as a PD-specific strategy:

| Metric | Score | Notes |
|--------|-------|-------|
| Investment Score | 5/10 | Smaller funding |
| Mechanism Score | 8/10 | α-Syn acetylation modulation |
| Clinical Score | 4/10 | Preclinical/Phase 1 |

Key Players:

Exsiccata Therapeutics: SIRT2 inhibitors
Academic programs: AGK2, AK-1 compounds

Mechanistic Rationale:

SIRT2 modulates α-synuclein acetylation
Inhibition reduces aggregate formation
Neuroprotective in PD models

Investment Thesis: Moderate for PD-specific, niche player opportunity.

SIRT3 Modulators

SIRT3 is the most promising sirtuin for mitochondrial protection:

| Metric | Score | Notes |
|--------|-------|-------|
| Investment Score | 7/10 | Mitochondrial focus, AD/PD |
| Mechanism Score | 9/10 | Strong mitochondrial data |
| Clinical Score | 6/10 | Early development |

Key Players:

MitoActives: SIRT3 activators
Academic programs

Mechanistic Rationale@brakedal2022:

Mitochondrial protein deacetylation
ROS scavenging enhancement
Metabolic enzyme regulation

Investment Thesis: High - mitochondrial dysfunction is core to neurodegeneration, SIRT3 is key regulator.

3. AMPK Activators

AMPK (AMP-activated protein kinase) is a central metabolic sensor and promising target:

| Metric | Score | Notes |
|--------|-------|-------|
| Investment Score | 7/10 | $90M+ deployed |
| Mechanism Score | 8/10 | Broad metabolic effects |
| Clinical Score | 6/10 | Repurposing opportunity |

Key Players@brakedal2022:

Meta Biotech: AICAR analogs
PharmaNostics: AMPK activators in repurposing

Small Molecule Activators:

AICAR (direct AMPK activator)
991 (perenteral)
A-769662 (direct)

Repurposing Candidates:

Metformin (indirect AMPK activator)
Thiazolidinediones (PPARγ-AMPK crosstalk)

Investment Thesis: High - approved drugs enable rapid clinical translation, strong mechanism.

Cross-Disease Investment Analysis

Alzheimer's Disease (AD)

| Target | Investment | Mechanism | Clinical | Tier |
|--------|------------|-----------|----------|------|
| NAD+ precursors | High | Strong | Phase 2 | Tier 1 |
| SIRT1 modulators | Moderate | Strong | Phase 0 | Tier 2 |
| SIRT3 modulators | Moderate | Strong | Preclinical | Tier 2 |
| AMPK activators | Moderate | Strong | Repurposing | Tier 2 |

Investment Rationale: AD represents largest market, metabolic dysfunction is core pathology, strong academicBig Pharma interest.

Parkinson's Disease (PD)

| Target | Investment | Mechanism | Clinical | Tier |
|--------|------------|-----------|----------|------|
| NAD+ precursors | High | Strong | Phase 2 | Tier 1 |
| SIRT2 inhibitors | Low | Moderate | Preclinical | Tier 2 |
| SIRT3 modulators | Moderate | Strong | Preclinical | Tier 2 |
| AMPK activators | Low | Moderate | Preclinical | Tier 2 |

Investment Rationale: PD second largest market, mitochondrial dysfunction is proven, smaller but dedicated pipeline.

ALS/FTD

| Target | Investment | Mechanism | Clinical | Tier |
|--------|------------|-----------|----------|------|
| Metabolic modulators | Moderate | Emerging | Phase 1 | Tier 2 |
| AMPK activators | Low | Moderate | Preclinical | Tier 3 |
| SIRT3 modulators | Low | Emerging | Preclinical | Tier 3 |

Investment Rationale: High unmet need, smaller market but premium pricing and fast regulatory pathways.

Investment Priority Matrix

Tier 1 - High Conviction (Execute)

| Therapeutic | Indication | Investment | Confidence |
|-------------|-------------|------------|------------|
| NAD+ precursors (NR/NMN) | AD/PD | $150M+ | A-1 |
| SIRT3 modulators | AD/PD | $50M+ | B+ |

Tier 2 - Speculative (Monitor)

| Therapeutic | Indication | Investment | Confidence |
|-------------|------------|------------|------------|
| SIRT1 activators | AD | $30M+ | B |
| SIRT2 inhibitors | PD | $15M+ | B- |
| AMPK activators | AD/PD/ALS | $90M+ | B+ |

Tier 3 - Research (Explore)

| Therapeutic | Indication | Investment | Confidence |
|-------------|------------|------------|------------|
| NMN analogs | AD | $20M+ | C+ |
| Novel sirtuins | FTD | $10M+ | C |

Causal Chain Analysis

NR→NAD+→SIRT1→Deacetylation→Neuroprotection

Mermaid diagram (expand to render)

Metabolic Dysfunction → Target → Intervention

Mermaid diagram (expand to render)

Company Pipeline Summary

| Company | Target | Indication | Stage | Funding |
|---------|--------|------------|-------|---------|
| ChromaDex | NAD+ (NR) | AD/PD | Public |
| Elevian | NAD+ precursors | AD | Series B |
| Al/ad Pharma | NR | PD | Series A |
| MitoActives | SIRT3 | AD/PD | Seed |
| Exsiccata | SIRT2 | PD | Seed |
| Meta Biotech | AMPK | AD/PD/ALS | Series A |

Knowledge Gaps

Phase 2/3 efficacy: NAD+ precursors need larger trials showing clinical cognitive/motor benefit

Biomarkers: Validated NAD+ level biomarkers in CNS for patient selection

Combination therapy: NAD+ with amyloid/tau or α-syn targeting

Delivery: Improved CNS delivery for NMN and sirtuin modulators

Patient stratification: Genetic markers predicting response (e.g., NAMPT variants)

Research Priorities

High Priority: NAD+ precursor Phase 2/3 trials with biomarker endpoints

High Priority: SIRT3 activator development through Phase 1

Medium Priority: AMPK activator repurposing in ALS

Medium Priority: Combination therapy trials (NAD+ + standard of care)

Low Priority: Novel sirtuin isoform selectivity

Strategic Implications

For Investors

Execute: NAD+ precursor companies have clearest path to Phase 2/3
Monitor: SIRT3 modulators for breakthrough potential in mitochondrial AD/PD
Avoid: Early-stage sirtuin programs with unclear PK/BBB crossing

For Biotech

Partner: Big Pharma interest in metabolic CNS is high
Validate: Use CNS NAD+ biomarkers for patient selection in trials
Differentiate: Novel delivery or combination approaches

For Pharma BD

Acquire: Early NAD+ platform companies before Phase 2 readouts
Partner: SIRT3 programs before IND-enabling studies
Monitor: AMPK activator repurposing in ALS/PD

Cross-Links

[Sirtuin Therapeutics Investment](/investment/sirtuin-therapeutics-neurodegeneration)
[Mitochondrial Therapeutics Investment](/investment/mitochondrial-therapeutics)
[Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings)
[Investment Signal Synthesis](/mechanisms/investment-signal-synthesis)
[AMPK Neurodegeneration](/mechanisms/ampk-neurodegeneration)
[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-neurodegeneration)

References

[Imai & Guarente, NAD+ and sirtuins in aging and disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24786309/)

[Brakedal et al., NAD+ metabolism in Parkinson's disease models (2022)](https://pubmed.ncbi.nlm.nih.gov/35027767/)

Pathway Diagram

The following diagram shows the key molecular relationships involving NAD+ Bioenergetics Investment Synthesis discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-nad-bioenergetics-investment-synthesis

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-nad-bioenergetics-investment-synthesis
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c6c91f8e21d6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-nad-bioenergetics-investment-synthesis'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

252

Outgoing

291

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NAD+ Bioenergetics Investment Synthesis

NAD+ Bioenergetics Investment Synthesis

Executive Summary

Investment Framework: Bioenergetics

Scoring Methodology

Therapeutic Target Analysis

1. NAD+ Precursors

Nicotinamide Riboside (NR)

NAD+ Bioenergetics Investment Synthesis

Executive Summary

Investment Framework: Bioenergetics

Scoring Methodology

Therapeutic Target Analysis

1. NAD+ Precursors

Nicotinamide Riboside (NR)

Nicotinamide Mononucleotide (NMN)

2. Sirtuin Modulators

SIRT1 Activators

SIRT2 Inhibitors (PD Target)

SIRT3 Modulators

3. AMPK Activators

Cross-Disease Investment Analysis

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

ALS/FTD

Investment Priority Matrix

Tier 1 - High Conviction (Execute)

Tier 2 - Speculative (Monitor)

Tier 3 - Research (Explore)

Causal Chain Analysis

NR→NAD+→SIRT1→Deacetylation→Neuroprotection

Metabolic Dysfunction → Target → Intervention

Company Pipeline Summary

Knowledge Gaps

Research Priorities

Strategic Implications

For Investors

For Biotech

For Pharma BD

Cross-Links

References

See Also

Pathway Diagram

💬 Discussion